Finder's Pick for
Beginners
Vir Biotechnology is a biotechnology business based in the US. Vir Biotechnology stocks (VIR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.65 – an increase of 7.89% over the previous week. Vir Biotechnology employs 444 staff and has a trailing 12-month revenue of around $2.3 billion.
How to buy stocks in Vir Biotechnology
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VIR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Finder's Pick for
Global Trading
Finder's Pick for
Commodity Stocks
Finder's Pick for
Free Trades
What's in this guide?
- Can I buy shares in Vir Biotechnology?
- Has coronavirus impacted Vir Biotechnology shares?
- Vir Biotechnology shares summary
- Compare share dealing platforms
- Is Vir Biotechnology stock a buy or sell?
- Vir Biotechnology performance over time
- Are Vir Biotechnology shares over-valued?
- Vir Biotechnology's financials
- How volatile are Vir Biotechnology shares?
- Does Vir Biotechnology pay a dividend?
- Other common questions
Vir Biotechnology stock price (NASDAQ:VIR)
Use our graph to track the performance of VIR stocks over time.Vir Biotechnology shares at a glance
Information last updated 2022-06-27.
| Latest market close | $26.65 |
|---|---|
| 52-week range | $18.21 - $58.00 |
| 50-day moving average | $23.19 |
| 200-day moving average | $32.30 |
| Wall St. target price | $52.71 |
| PE ratio | 2.7628 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $8.99 |
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
1 - 6 of 6
Online stock trading
Is it a good time to buy Vir Biotechnology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Vir Biotechnology price performance over time
Historical closes compared with the close of $26.65 from 2022-06-27
| 1 week (2022-06-21) | 7.89% |
|---|---|
| 1 month (2022-05-27) | -0.19% |
| 3 months (2022-03-28) | 25.77% |
| 6 months (2021-12-28) | -32.33% |
| 1 year (2021-06-28) | -43.14% |
|---|---|
| 2 years (2020-06-26) | -31.37% |
| 3 years (2019-06-24) | N/A |
| 5 years (2017-06-24) | N/A |
Is Vir Biotechnology under- or over-valued?
Valuing Vir Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vir Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vir Biotechnology's P/E ratio
Vir Biotechnology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Vir Biotechnology shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Vir Biotechnology's EBITDA
Vir Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 billion.
The EBITDA is a measure of a Vir Biotechnology's overall financial performance and is widely used to measure a its profitability.
Vir Biotechnology financials
| Revenue TTM | $2.3 billion |
|---|---|
| Operating margin TTM | 70.59% |
| Gross profit TTM | $590.7 million |
| Return on assets TTM | 51.02% |
| Return on equity TTM | 91.71% |
| Profit margin | 52.29% |
| Book value | $15.12 |
| Market capitalisation | $3.3 billion |
TTM: trailing 12 months
Vir Biotechnology share dividends
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Vir Biotechnology share price volatility
Over the last 12 months, Vir Biotechnology's shares have ranged in value from as little as $18.21 up to $58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vir Biotechnology's is -0.5804. This would suggest that Vir Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vir Biotechnology has bucked the trend.
Vir Biotechnology overview
Vir Biotechnology, Inc. , a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; license agreements with The Rockefeller University and MedImmune, Inc. ; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd. ; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
Vir Biotechnology in the news
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
Find the best investment newsletters in Canada
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Read more…
Sectors and stocks that might protect you from rising interest rates
Here are some investment ideas that could do well despite rising interest rates.
Read more…
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…More guides on Finder
-
How to buy Acadian Timber stock in Canada
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
-
How to buy Mobilicom Limited (MOB) stock in Canada when it goes public
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
-
How to buy Consumer Staples Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
-
How to buy Schwab U.S. REIT ETF stock in Canada
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
-
How to buy iShares US Consumer Staples ETF stock in Canada
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
-
How to buy Vanguard Real Estate Index Fund ETF Shares stock in Canada
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
-
How to buy SPDR S&P Insurance ETF stock in Canada
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
-
How to buy Financial Select Sector SPDR Fund stock in Canada
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
-
How to buy Invesco Dynamic Energy Exploration-and-Production ETF stock in Canada
Steps to owning and managing PXE stock, with 24-hour and historical pricing before you buy.
-
How to buy First Trust Natural Gas ETF stock in Canada
Steps to owning and managing FCG stock, with 24-hour and historical pricing before you buy.